141 related articles for article (PubMed ID: 11025699)
41. Absence of p53 overexpression and favorable response to cisplatin-based neoadjuvant chemotherapy in urothelial carcinomas.
Kakehi Y; Ozdemir E; Habuchi T; Yamabe H; Hashimura T; Katsura Y; Yoshida O
Jpn J Cancer Res; 1998 Feb; 89(2):214-20. PubMed ID: 9548450
[TBL] [Abstract][Full Text] [Related]
42. [Clinical results of IV-compa (cisplatin, vincristine, methotrexate, peplomycin and adriamycin) chemotherapy for advanced urothelial cancer].
Tsujino S; Ono Y; Yamamoto S; Tsuzuki M; Miki M; Aizawa T; Matsumoto T; Yamauchi T
Nihon Hinyokika Gakkai Zasshi; 1995 Jun; 86(6):1164-71. PubMed ID: 7609360
[TBL] [Abstract][Full Text] [Related]
43. Paclitaxel in advanced urothelial carcinoma: its role in patients with renal insufficiency and as salvage therapy.
Dreicer R; Gustin DM; See WA; Williams RD
J Urol; 1996 Nov; 156(5):1606-8. PubMed ID: 8863548
[TBL] [Abstract][Full Text] [Related]
44. Cross-resistance and combined cytotoxic effects of paclitaxel and cisplatin in bladder cancer cells.
Pu YS; Chen J; Huang CY; Guan JY; Lu SH; Hour TC
J Urol; 2001 Jun; 165(6 Pt 1):2082-5. PubMed ID: 11371932
[TBL] [Abstract][Full Text] [Related]
45. Phase II Clinical and Translational Study of Everolimus ± Paclitaxel as First-Line Therapy in Cisplatin-Ineligible Advanced Urothelial Carcinoma.
Jun T; Hahn NM; Sonpavde G; Albany C; MacVicar GR; Hauke R; Fleming M; Gourdin T; Jana B; Oh WK; Taik P; Wang H; Varadarajan AR; Uzilov A; Galsky MD
Oncologist; 2022 Jun; 27(6):432-e452. PubMed ID: 35438782
[TBL] [Abstract][Full Text] [Related]
46. The pretreatment neutrophil-to-lymphocyte ratio is a novel biomarker for predicting clinical responses to pembrolizumab in platinum-resistant metastatic urothelial carcinoma patients.
Ogihara K; Kikuchi E; Shigeta K; Okabe T; Hattori S; Yamashita R; Yoshimine S; Shirotake S; Nakazawa R; Matsumoto K; Mizuno R; Hara S; Oyama M; Masuda T; Niwakawa M; Oya M
Urol Oncol; 2020 Jun; 38(6):602.e1-602.e10. PubMed ID: 32139290
[TBL] [Abstract][Full Text] [Related]
47. Prolonged Remission of Upper Urinary Tract Urothelial Carcinoma With Prominent Choriocarcinomatous Differentiation: A Case Report.
Msaouel P; Zhang M; Tu SM
Clin Genitourin Cancer; 2017 Feb; 15(1):e73-e77. PubMed ID: 27692813
[No Abstract] [Full Text] [Related]
48. Phase II trial of cetuximab with or without paclitaxel in patients with advanced urothelial tract carcinoma.
Wong YN; Litwin S; Vaughn D; Cohen S; Plimack ER; Lee J; Song W; Dabrow M; Brody M; Tuttle H; Hudes G
J Clin Oncol; 2012 Oct; 30(28):3545-51. PubMed ID: 22927525
[TBL] [Abstract][Full Text] [Related]
49. Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody-Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma.
Sheng X; Yan X; Wang L; Shi Y; Yao X; Luo H; Shi B; Liu J; He Z; Yu G; Ying J; Han W; Hu C; Ling Y; Chi Z; Cui C; Si L; Fang J; Zhou A; Guo J
Clin Cancer Res; 2021 Jan; 27(1):43-51. PubMed ID: 33109737
[TBL] [Abstract][Full Text] [Related]
50. Bladder cancer: second-line nab-paclitaxel for advanced urothelial carcinoma.
Payton S
Nat Rev Urol; 2013 Aug; 10(8):431. PubMed ID: 23752991
[No Abstract] [Full Text] [Related]
51. A case for preoperative chemotherapy in advanced urothelial cancer of the upper urinary tract.
Jakse G; Schmid KW
Eur Urol; 1986; 12(6):387-9. PubMed ID: 3816892
[TBL] [Abstract][Full Text] [Related]
52. A new approach to second-line therapy for urothelial cancer?
Sonpavde G; Galsky MD; Bellmunt J
Lancet Oncol; 2013 Jul; 14(8):682-4. PubMed ID: 23706984
[No Abstract] [Full Text] [Related]
53. Commentary on "Phase II trial of cetuximab with or without paclitaxel in patients with advanced urothelial tract carcinoma." Wong YN, Litwin S, Vaughn D, Cohen S, Plimack ER, Lee J, Song W, Dabrow M, Brody M, Tuttle H, Hudes G, University of Pennsylvania, Philadelphia, PA: J Clin Oncol 2012;30(28):3545-51 [Epub 2012 Aug 27].
Kamat AM
Urol Oncol; 2013 Jul; 31(5):719. PubMed ID: 23796204
[TBL] [Abstract][Full Text] [Related]
54. Chemotherapy in the management of invasive and metastatic bladder cancer.
Raghavan D
Eur Urol; 1988; 14 Suppl 1():21-3. PubMed ID: 3053200
[No Abstract] [Full Text] [Related]
55. Intracellular glutathione content of urothelial cancer in correlation to chemotherapy response.
Yang CR; Ou YC; Kuo JH; Kao YL; Chen CL; Yean SY; Horng YY; Yang CS
Cancer Lett; 1997 Nov; 119(2):157-62. PubMed ID: 9570366
[TBL] [Abstract][Full Text] [Related]
56. [Combination effects of CDDP, ACR and HCFU on progressive urothelial tumors].
Ueda K; Jinno H; Watanabe H; Ohtaguro K
Gan To Kagaku Ryoho; 1985 Jun; 12(6):1318-22. PubMed ID: 3859251
[TBL] [Abstract][Full Text] [Related]
57. [Neoadjuvant chemotherapy in patients with high-risk upper tract urothelial carcinoma: current evidence].
Bolenz C; Zengerling F
Urologie; 2023 May; 62(5):522-524. PubMed ID: 37076603
[No Abstract] [Full Text] [Related]
58. Nodules in scrotum. Manifestation of urothelial carcinoma.
Arrabal-Polo MÁ; del Carmen Cano-García M; Fabiano P
Int Urol Nephrol; 2015 Jul; 47(7):1155-6. PubMed ID: 25943265
[No Abstract] [Full Text] [Related]
59. Peripheral sensory neuropathy and cisplatin chemotherapy.
Roelofs RI; Hrushesky W; Rogin J; Rosenberg L
Neurology; 1984 Jul; 34(7):934-8. PubMed ID: 6330613
[TBL] [Abstract][Full Text] [Related]
60. Significant advances in chemotherapy for both urothelial and renal cancer.
BJU Int; 2024 Feb; 133(2):122-123. PubMed ID: 38232742
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
